FDA reviews Iso-Tex Diagnostics, Inc. in Alvin on Feb. 3 for quality compliance

Sean R. Keveney J.D., Chief Counsel of FDA
Sean R. Keveney J.D., Chief Counsel of FDA
0Comments

The Food and Drug Administration (FDA) inspected Iso-Tex Diagnostics, Inc. in Alvin on Feb. 3 to assess drug quality assurance, as shown by data on the FDA’s website.

The inspection’s final report recommended that Iso-Tex Diagnostics, Inc. implement official corrective actions in the organization’s management operations.

The FDA regularly conducts inspections of facilities nationwide to verify compliance with agency laws and regulations that support public health. Inspection outcomes are made publicly accessible.

The agency’s website states the FDA is primarily charged with overseeing the production and distribution of human and animal drugs, biological products, medical devices, and tobacco products to ensure safety and quality.

Information in this article was obtained from the U.S. Food and Drug Administration. The source data can be found here.



Related

David Mayes Middleton, Texas State Senator from 11th District (R)

Mayes Middleton comments on Texas GOP leadership and energy policy in recent tweets

Mayes Middleton, Republican state senator for Texas’s 11th district, used Twitter between June 13 and June 15, 2026, to congratulate Drinda Randall on her appointment as chairwoman of the Republican Party of Texas and comment on grassroots…

Dennis Paul, Texas State Representative of 129th District (R)

Dennis Paul highlights Artemis III crew and GOP convention activities in recent posts

Dennis Paul used his Twitter account in June 2026 to congratulate the Artemis III crew and document activities at the Republican Party of Texas Convention, including meetings with key state officials and representatives

Dr. Mehmet Oz CMS Administrator

Alvin Medicaid spending for Temporary National Codes (Non-Medicare) tops $4 million in 2024

Medicaid payments associated with the Temporary National Codes (Non-Medicare) category in Alvin rose 4.6% to $4,011,836 in 2024, signaling shifts in service utilization and reimbursement.